(Q33180616)

23 July 2017

1 reference

title

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases (English)

1 reference

23 July 2017

1 reference

Herrmann ML

1

1 reference

23 July 2017

Schleyerbach R

series ordinal

2

1 reference

23 July 2017

Kirschbaum BJ

series ordinal

3

1 reference

23 July 2017

language of work or name

1 reference

1 May 2000

1 reference

23 July 2017

1 reference

23 July 2017

47

1 reference

23 July 2017

2-3

1 reference

23 July 2017

273-289

1 reference

A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Immunopharmacological profile of HWA 486, a novel isoxazol derivative--II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Effects of leflunomide on immune responses and models of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inositol phosphates and cell signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Rheumatoid arthritis complicated by infection with the human immunodeficiency virus and the development of Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

T cells and related cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

T and B cell-dependent pathways in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Nucleoside and nucleobase transport systems of mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

New concepts in treatment protocols for severe systemic vasculitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Immune regulation by the ST6Gal sialyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Understanding and controlling the cell cycle with natural products

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Cell cycle regulation of membrane phospholipid metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Pyrimidine Nucleotide Biosynthesis in Animals: Genes, Enzymes, and Regulation of UMP Biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Regulation of eukaryotic phospholipid metabolism 1

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Suppressor T cells in mice made unresponsive to skin allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Organ-specific disease provoked by systemic autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Tyrosine kinase inhibition: an approach to drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Anergic T cells as suppressor cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Blood distribution and single-dose pharmacokinetics of leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Studies on the incorporation of precursors into purine and pyrimidine nucleotides via 'de novo' and 'salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

De novo synthesis of pyrimidine nucleotides by Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

A fistful of T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Appearance of CAD activity, the rate-limiting enzyme for pyrimidine biosynthesis, as B cells progress into and through the G1 stage of the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Molecular and cellular interactions in rheumatoid synovium.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

The role of low-dose PALA in biochemical modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Lymphocyte responses and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Glycoproteins: what are the sugar chains for?

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

"Infectious" transplantation tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Synovial tissue response to treatment with Campath-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Enzymes of nucleotide biosynthesis: differences between intact and lysed cells as well as between species and tissues can be important

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Leflunomide prevents the development of experimentally induced myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Perturbation of the T cell repertoire in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Uridine transport in concanavalin A- and lipopolysaccharide-activated mouse lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900191-0

7 January 2021

10.1016/S0162-3109(00)00191-0

Identifiers

DOI

1 reference

23 July 2017

1 reference